Journal article
Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody
Abstract
PurposeTargeted radionuclide therapy against cancer stem cell-specific markers, such as CD133, constitutes a promising strategy to eliminate resilient cancer stem cells for improved outcomes in refractory tumors. Here, we report the synthesis and evaluation of [177Lu]Lu-DOTA-RW03, a CD133-targeted radioimmunotherapy.ProceduresA fully human, anti-CD133 antibody (RW03) was conjugated with DOTA-NHS and radiolabeled with lutetium-177 to yield …
Authors
Wyszatko K; Janzen N; Law N; Ventura M; Komal T; Savage N; Venugopal C; Kwiecien JM; Singh SK; Sadeghi S
Journal
Molecular Imaging and Biology, Vol. 27, No. 4, pp. 606–616
Publisher
Springer Nature
Publication Date
8 2025
DOI
10.1007/s11307-025-02013-4
ISSN
1536-1632